Genomics and gene editing companies aim to treat disease at its genetic root. In 2026, investors are focused on which platforms can translate scientific breakthroughs into approved therapies while navigating long clinical and regulatory timelines.
This page highlights genomics and gene editing stocks to watch in 2026 across CRISPR platforms, next-generation editing technologies, and genomics infrastructure.
Trial readouts drive valuation inflection points.
Base and prime editing reduce off-target risks.
Safe and effective delivery remains a key bottleneck.
Long development cycles require strong balance sheets.
CRISPR Therapeutics
Mid-cap, platform leader
CRISPR Therapeutics develops gene-edited therapies using CRISPR-Cas9 technology.
Intellia Therapeutics
Mid-cap, CRISPR innovator
Intellia focuses on in vivo CRISPR-based gene editing therapies.
Editas Medicine
Small-cap, early-stage
Editas develops CRISPR-based gene editing medicines.
Beam Therapeutics
Mid-cap, next-gen editing
Beam develops base editing technologies for precise gene modification.
Verve Therapeutics
Small-cap, focused pipeline
Verve develops gene editing therapies for cardiovascular disease.
Illumina
Large-cap, infrastructure leader
Illumina provides DNA sequencing systems used across genomics research.
Pacific Biosciences
Mid-cap, genomics technology
Pacific Biosciences develops long-read DNA sequencing platforms.
Regeneron Pharmaceuticals
Large-cap, biotech leader
Regeneron integrates genetics into drug discovery and development.
Vertex Pharmaceuticals
Large-cap, commercial execution
Vertex develops genetic therapies for rare diseases.
10x Genomics
Mid-cap, genomics tools
10x Genomics provides tools for single-cell and spatial genomics.
CRISPR and next-generation gene editing technologies.
Sequencing and genomics tools enabling research.
Large biotech firms integrating genomics into drug development.
This list highlights genomics and gene editing companies with differentiated platforms, strong scientific foundations, and strategic partnerships. Selection emphasizes platform optionality, pipeline depth, and public market relevance.
Yes, but approvals are limited to specific indications.
Safe, targeted delivery to the correct cells.
As a small, high-upside allocation within a diversified portfolio.
Before you invest in this theme, learn the fundamentals
Courses on picking stocks, building ETF portfolios and valuing companies.
Udemy
Stock Trading: Invest and Trade Safely with Stock Sector ETF
Stock Lovers, Traders, Investors, Stock Market Aficionados! Master the basics of trading ETFs. NO NEED to pick and choose individual…
View course
Udemy
Value Stock Market Investing: Invest In Undervalued Stocks
This course is designed to teach investors the principles and techniques of value investing, a proven investment strategy used by some of…
View course
Udemy
Stock Market for Beginners: Start Smart, Invest Wisely
A self-paced video course on investing basics and stock investing, with practical lessons you can apply right away.
View course
Last updated: 2026-01-17
This content is for educational purposes only and does not constitute financial advice.